We are seeking a highly collaborative, hands-on Scientist II to help establish a preclinical neuroscience laboratory supporting small-molecule and protein therapeutics. The immediate priorities are rapid cellular profiling and lead selection for an advanced small-molecule enzyme program, and leadership of cellular development for a transferrin-based protein replacement project. The role will also build fit-for-purpose human neuronal models, laboratory workflows, and external partnerships.
We welcome applications from candidates located across the Northeast and Mid-Atlantic.
Lead a rapid, tiered cellular assay strategy for small-molecule lead optimization, including target engagement, pharmacodynamics, concentration-response, duration, selectivity, neuronal phenotype, stress, and tolerability
Lead cellular development of a transferrin-based protein replacement project by establishing quantitative assays for construct uptake, internalization, intracellular trafficking, protein abundance and integrity, mitochondrial response, and disease-relevant phenotypic rescue
Use orthogonal methods to distinguish surface-bound, internalized, degraded, and functionally delivered protein; compare constructs and define advancement criteria
Establish fit-for-purpose neuronal culture models, including iPSC-derived neurons or glia where they add decision value, with appropriate banking and quality control
Define assay controls, acceptance criteria, reproducibility standards, analysis plans, SOPs, sample tracking, and electronic documentation
Translate data into concise recommendations to advance, modify, or discontinue assets
Partner across protein engineering, chemistry, bioanalysis, DMPK, pathology, computational biology, and in vivo pharmacology; scientifically manage CROs and assay transfers
Mentor junior scientists and build workflows that are reproducible across operators. Future scope may include ASO screening in partnership with external experts
Enzyme biology, epigenetics, or transcriptional pharmacology; therapeutic proteins or targeted-delivery constructs; cellular uptake, trafficking, or protein quantification; mitochondrial functional assays; high-content imaging or neuronal functional assays; transferrin receptor biology, BBB transport, or biodistribution; laboratory start-up, assay transfer, or CRO management
Exposure to ASO screening or RNA pharmacology is beneficial
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
